Physician profile
Jack Nussbaum
NPI 1346242690
$10,743.90
in general payments reported to CMS, 2019-2025
40 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $1,413 · 2021: $1,521 · 2022: $1,524 · 2023: $1,749 · 2024: $1,429 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,699.64 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,511.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,270.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.01 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $697.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $538.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $464.23 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $430.49 | 2019-2022 | |
| Amgen INC. | $367.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $312.35 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $253.12 | 2019-2025 | Eliquis |
| Daiichi Sankyo INC. | $235.04 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $226.62 | 2019-2022 | |
| Exact Sciences Corporation | $212.21 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $172.13 | 2020-2025 | Veozah, Myrbetriq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Nussbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.